
Sign up to save your podcasts
Or


William H. Sauer, MD, FHRS, CCDS, of Brigham and Women's Hospital is joined by guests Thomas Tadros, MD, and Ashraf Sabe, MD, of Brigham and Women's Hospital, to discuss efficacy and safety of hybrid epicardial and endocardial ablation versus endocardial ablation in patients with persistent and longstanding persistent atrial fibrillation. In this randomized trial, hybrid surgical and catheter ablation was more effective than catheter ablation alone in persistent atrial fibrillation without significant procedural risk increase.
https://www.hrsonline.org/education/TheLead
https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(23)00229-8/fulltext
Host Disclosure(s):
W. Sauer: Honoraria/Speaking/Consulting Fee: Biotronik, Biosense Webster, Inc., Abbott, Boston Scientific; Research (Contracted Grants for PIs Named Investigators Only): Medtronic
Contributor Disclosure(s):
T. Tadros: No relevant financial relationships with ineligible companies to disclose.
A. Sabe: No relevant financial relationships with ineligible companies to disclose.
By The Lead Podcast presented by Heart Rhythm Society5
77 ratings
William H. Sauer, MD, FHRS, CCDS, of Brigham and Women's Hospital is joined by guests Thomas Tadros, MD, and Ashraf Sabe, MD, of Brigham and Women's Hospital, to discuss efficacy and safety of hybrid epicardial and endocardial ablation versus endocardial ablation in patients with persistent and longstanding persistent atrial fibrillation. In this randomized trial, hybrid surgical and catheter ablation was more effective than catheter ablation alone in persistent atrial fibrillation without significant procedural risk increase.
https://www.hrsonline.org/education/TheLead
https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(23)00229-8/fulltext
Host Disclosure(s):
W. Sauer: Honoraria/Speaking/Consulting Fee: Biotronik, Biosense Webster, Inc., Abbott, Boston Scientific; Research (Contracted Grants for PIs Named Investigators Only): Medtronic
Contributor Disclosure(s):
T. Tadros: No relevant financial relationships with ineligible companies to disclose.
A. Sabe: No relevant financial relationships with ineligible companies to disclose.

320 Listeners

498 Listeners

169 Listeners

885 Listeners

3,344 Listeners

140 Listeners

9,137 Listeners

195 Listeners

364 Listeners

431 Listeners

371 Listeners

29,209 Listeners

4 Listeners

3 Listeners

0 Listeners